Full-Time
Operations & Analytics Analyst
Orca Bio
201-500 employees
Develops and commercializes safer cell therapies
Compensation Overview
$70k - $90k/yr
Menlo Park, CA, USA
In Person
Bachelor's
 Business & Strategy (1) |
|---|
Get referred to Orca Bio
See people who can refer or advise you
- A bachelor's degree in a life sciences or related scientific field, such as biology, biochemistry, public health, or a similar field.
- 0–2 years of experience; new graduates or candidates with 1–2 years in consulting or biopharma are welcome to apply.
- Demonstrated interest in cell and gene therapy through coursework, research, internships, or applied experience.
- Strong Excel and analytical skills, with comfort working across data and systems.
- Demonstrated fluency with artificial intelligence tools such as Claude, ChatGPT, or Gemini, and genuine curiosity about applying them to real business problems.
- Serve as a forward-deployed engineer on Project Sonar by embedding with teams across commercial, supply, logistics, technical operations, manufacturing, and other functions to understand workflows and identify where artificial intelligence can remove friction.
- Translate business needs into artificial-intelligence-developed solutions by scoping problems with functional teams, building and iterating solutions with the engineering team, and handing off working tools.
- Build and maintain artificial intelligence agents, assistants, and automated workflows using approved company platforms.
- Lead ongoing maintenance of the enterprise data ecosystem, including Salesforce, Power BI or Tableau, enterprise resource planning systems, the data warehouse, customer relationship management integration, and reporting infrastructure supporting performance tracking and business decisions.
- Support United States demand and revenue forecasts for TREGZI and connect commercial demand signals to supply, manufacturing, and capacity planning.
- Support supply chain and logistics planning, including chain-of-identity and chain-of-custody workflows, courier and shipping coordination, and scheduling across collection, manufacturing, and infusion.
- Build and maintain trackers, dashboards, and analyses for manufacturing throughput, slot utilization, turnaround time, on-time delivery, and deviations.
- Partner with Technical Operations on capacity modeling, scenario planning, and analyses informing manufacturing and network decisions.
- Support site activation and onboarding by tracking engagement and readiness metrics, maintaining trackers across the qualified-center footprint, and supporting communications and workflows for treatment and transplant center onboarding.
- Support market sizing, landscape research, and opportunity assessments for pipeline programs across multiple indications.
- Exposure to customer relationship management and business intelligence platforms such as Salesforce, Tableau, or Power BI.
- Hands-on experience building with artificial intelligence, including prompt engineering, agent or workflow automation, and light scripting with Python or SQL.
- Curiosity, comfort with ambiguity, and eagerness to learn in a fast-paced, launch-focused environment.
Orca Bio develops and commercializes cell therapies to improve outcomes for patients. It works by researching, developing, and producing therapies that use the body’s own cells to treat diseases, with products sold to healthcare providers who administer them to patients. The company aims to enhance the safety and effectiveness of cell therapies, making treatments more reliable for conditions that lack good options. Orca Bio differentiates itself through its focus on delivering safer, more effective therapies and by fostering a strong team culture with active stakeholder communication, including a regularly updated newsroom. Overall, its goal is to expand access to improved cell therapies and become a leading player in the cell therapy market.
Company Size
201-500
Company Stage
Series F
Total Funding
$542M
Headquarters
Menlo Park, California
Founded
2016
Get referred to Orca Bio
See people who can refer or advise you
Simplify's Take
What believers are saying
- FDA approval on June 30, 2026 validates Orca Bio's platform and pipeline.
- The company raised $250 million in December 2025, funding launch and expansion.
- Princeton capacity and Sacramento hiring support commercialization and faster nationwide patient delivery.
What critics are saying
- TREGZI costs $428,000, forcing transplant centers and payers into tough coverage fights.
- Complex donor-specific manufacturing can bottleneck supply, delaying launches beyond the planned 25 centers.
- Any post-marketing safety signal or FDA CMC issue would cripple Orca Bio's only commercial product.
What makes Orca Bio unique
- Orca Bio's TREGZI won FDA approval on June 30, 2026, first precision cell therapy.
- Its donor-derived regulatory T-cell design directly reduces chronic GVHD after transplant.
- Princeton and Sacramento manufacturing create a bicoastal vein-to-vein network for personalized production.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Unlimited Paid Time Off
401(k) Retirement Plan
Parental Leave
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 2%2 year growth
↓ -3%The US Food and Drug Administration has approved Tregzi, the first regulatory T cell-based immunotherapy for improving chronic graft-versus-host disease-free survival in adult blood cancer patients undergoing stem cell transplantation. The treatment uses donor-derived immune cells to help fight cancer whilst reducing the risk of chronic GVHD, a serious complication where transplanted donor cells attack the patient's body. In the PRECISION-T trial involving 187 patients, 78% of those receiving Tregzi achieved chronic GVHD-free survival at one year, compared to 38.4% receiving standard transplants. Only 12.6% of Tregzi patients developed serious chronic GVHD within one year versus 44% in the control group. The treatment, developed by Orca Biosystems, received Orphan Drug and Regenerative Medicine Advanced Therapy designations.
Orca Bio has secured FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants. The allogeneic regulatory T cell-based immunotherapy is approved as an alternative stem cell transplant to improve survival free of chronic graft-versus-host disease in adults with hematological malignancies. In the phase 3 Precision-T trial involving 187 patients, 78% who received Tregzi were alive and free from chronic GVHD at one year, compared to 38% with standard transplants—a 74% improvement. Overall survival was 94% versus 83%. Orca is pricing Tregzi at $428,000 wholesale acquisition cost. The company recently raised $250 million and is launching at select centres, aiming for 25 by year-end. CEO Nate Fernhoff said the company is "well capitalised" for launch but didn't rule out a future IPO.
Orca Bio has received US FDA approval for TREGZI, the first precision-engineered cell therapy for matched-donor hematopoietic stem cell transplantation in adults with hematological malignancies. The therapy uses donor cells to reconstitute the immune system whilst suppressing graft-versus-host disease (GVHD). The approval is based on the Phase 3 Precision-T study of 187 patients with acute myeloid leukaemia, acute lymphoblastic leukaemia, myelodysplastic syndrome and mixed-phenotype acute leukaemia. Results showed 78% chronic GVHD-free survival at 12 months with TREGZI compared to 38% with conventional transplant. Overall survival was 94% versus 83%, whilst non-relapse mortality was 3% compared to 13%. TREGZI is a personalised treatment manufactured for each patient using living cells from a matched donor.
Orca Bio expands Sacramento workforce, adds East Coast manufacturing site ahead of approval. June 15, 2026 san francisco biotechnology network news news, syndication comments off on orca Bio expands Sacramento workforce, adds East Coast manufacturing site ahead of approval. Orca Bio, a biotechnology company that works in precision cell therapy, has expanded its Sacramento workforce and added an East Coast manufacturing center in Princeton, New Jersey, as it prepares for commercialization. Click here to view original post
Orca Bio has expanded its manufacturing capabilities ahead of the potential launch of its lead cell therapy, Orca-T, adding East Coast manufacturing capacity in Princeton, New Jersey, and tripling its West Coast manufacturing workforce in Sacramento, California. The Princeton facility will serve as a strategic East Coast manufacturing bridge, initially producing therapies for ongoing clinical programmes and supporting commercial production following potential FDA approval. The bicoastal network aims to reduce "vein-to-vein" time for patients nationwide. Orca Bio has more than tripled its Sacramento operations team over the past year, enhancing expertise in manufacturing, supply chain logistics and quality assurance. Orca-T's Biologics License Application is under FDA review, with a target action date of 6 July 2026.